Antitrust Laws in Healthcare: Violations, Mergers, and Exemptions

Antitrust laws in healthcare come from four federal statutes — the Sherman Act, the Clayton Act, the Federal Trade Commission Act, and the Robinson-Patman Act — enforced by the Department of Justice, the Federal Trade Commission, and state attorneys general. Together they prohibit price-fixing, wage-fixing, no-poach agreements, monopolization, and mergers that substantially lessen competition, while permitting collaborations among providers that are genuinely integrated rather than pricing cartels in disguise. Healthcare gets particular attention because patients rarely comparison-shop in emergencies, insurers negotiate for millions at once, and consolidation among hospitals or physician groups can quietly erase the competition that keeps prices down.

The Statutes That Apply

The Sherman Act, passed in 1890, is the broadest of the four. Section 1 prohibits agreements between competitors that unreasonably restrain trade. Section 2 makes it illegal to monopolize a market, or attempt to, through exclusionary conduct rather than by competing on the merits.¹ Both are felonies. The maximum criminal penalty is a $100 million fine for a corporation, a $1 million fine for an individual, and up to 10 years in prison.²

The Clayton Act of 1914 targets practices the Sherman Act doesn’t neatly reach. Section 7 prohibits mergers and acquisitions where the effect “may be substantially to lessen competition, or to tend to create a monopoly” in any market.³ This is the statute regulators use to challenge hospital mergers, physician group acquisitions, and insurer consolidation. The Clayton Act also lets private parties harmed by anti-competitive conduct sue for triple their actual damages.⁴

The FTC Act of 1914 created the Federal Trade Commission and gives it authority to prevent “unfair methods of competition” and “unfair or deceptive acts or practices” affecting commerce.⁵ Its language is deliberately broad, letting the Commission reach conduct that doesn’t fit neatly into the Sherman or Clayton categories.⁶

The Robinson-Patman Act prohibits sellers from charging different prices to different buyers for commodities of the same grade and quality when the difference may substantially lessen competition.⁷ In healthcare it’s most relevant to pharmaceutical sales, where manufacturers have historically offered deep discounts to hospitals and health plans while charging pharmacies more for the same drugs. Enforcement has been rare in recent decades, and drug makers have shifted toward post-sale rebates rather than upfront discounts to sidestep its restrictions.

Who Enforces the Rules

Federal enforcement is shared between the DOJ Antitrust Division and the FTC. The DOJ’s Healthcare and Consumer Products Section handles health insurance mergers and investigates provider and insurer transactions, often coordinating with the FTC, state attorneys general, and state insurance regulators.⁸ Only the DOJ brings criminal antitrust prosecutions, typically for price-fixing, bid-rigging, or wage-fixing conspiracies. The FTC focuses on civil enforcement and has been particularly active on hospital mergers and physician group acquisitions.⁹

State attorneys general enforce both federal antitrust statutes (under authority granted by the Clayton Act) and their own state competition laws. Nearly every state has an antitrust statute prohibiting price-fixing and monopolization, and AGs can act individually or in multistate coalitions.¹⁰ Private plaintiffs add a fourth enforcement track through Clayton Act treble-damages suits.

Conduct That Violates the Law

Enforcement distinguishes between agreements among competitors and unilateral monopolistic conduct, and uses two different analytical frameworks depending on how obviously harmful the behavior is.

Per Se Violations

Some agreements are so inherently destructive to competition that courts don’t weigh possible benefits. These per se violations include price-fixing, market allocation (dividing up territories or patient populations), and coordinated boycotts.¹ Even informal conversations between independent physicians about fees can trigger a price-fixing investigation. Two practices agreeing not to accept rates below a certain threshold, or three surgeons carving a metro area into exclusive territories, are textbook violations.

Wage-Fixing and No-Poach Agreements

Labor-side agreements deserve separate attention because they’re increasingly common and many healthcare employers don’t realize they’re committing felonies. When competing hospitals or staffing agencies agree not to recruit each other’s nurses, or coordinate pay rates to suppress wages, the DOJ treats those agreements as per se violations subject to criminal prosecution. Since 2016, the DOJ has pursued these criminally rather than civilly. In United States v. Lopez, a federal jury convicted a home health agency executive in Nevada for conspiring to fix wages for home healthcare nurses over a three-year period — the DOJ’s first criminal trial victory for wage-fixing under the Sherman Act.¹¹

Monopolization

Section 2 of the Sherman Act prohibits using exclusionary conduct to acquire or maintain monopoly power. The key line is between growing dominant through superior service and growing dominant by locking out competitors. A hospital that attracts patients because it has the best cardiac surgeons in the region hasn’t violated the law. A hospital that signs exclusive contracts with every insurer in the area specifically to starve a new competitor of patients may have.¹ Monopolization can be prosecuted criminally or civilly, though civil suits seeking injunctions are more common.

Rule of Reason Conduct

Behavior that doesn’t fall into a per se category is evaluated under the Rule of Reason, which weighs anti-competitive harm against pro-competitive benefits. This is a more forgiving standard. A hospital system that requires its employed physicians to refer within the network might survive Rule of Reason analysis if the arrangement improves care coordination and the restrictions are no broader than needed to achieve that benefit.

Mergers and Acquisitions

Under Clayton Act Section 7, the analysis of a proposed deal starts with two questions: what’s the product market, and what’s the geographic market?³ For hospital mergers, the product market is usually general acute care inpatient services, because outpatient clinics and urgent care centers aren’t realistic substitutes for someone who needs surgery or intensive care. The geographic market analysis asks whether patients would travel outside the proposed area for care if prices rose.¹² Both horizontal deals (competing hospitals combining) and vertical deals (a hospital acquiring a physician group that refers to it) face scrutiny.

Hart-Scott-Rodino Filing

Merging parties must file a pre-merger notification under the Hart-Scott-Rodino Act when the transaction value exceeds the applicable threshold. For 2026, the basic size-of-transaction threshold is $133.9 million.¹³ After filing, the parties must wait 30 days (15 days for cash tender offers or bankruptcy transactions) before closing.¹⁴ The agencies use that window to decide whether to investigate further.

Remedies When Regulators Object

When regulators conclude a proposed merger would harm competition but blocking the entire deal seems disproportionate, they often require divestitures. The standard remedy for a horizontal healthcare merger is selling off an autonomous, ongoing business unit to a buyer capable of competing independently. If the divestiture package is less than a standalone business, the FTC typically requires the parties to identify a buyer up front before the deal closes, so the divested assets don’t deteriorate during the transition.¹⁵

Recent Deals Challenged

In 2024, the FTC sued to block Novant Health’s $320 million acquisition of two North Carolina hospitals from Community Health Systems; the deal was eventually abandoned. FTC staff also successfully urged Indiana regulators to deny a proposed merger between two Terre Haute hospitals. In late 2025, Aya Healthcare terminated its proposed acquisition of Cross Country Healthcare after the FTC signaled opposition.¹⁶ Deals that significantly reduce competition in a local market face real risk of being challenged.

Collaborations That Are Allowed

Not every agreement among competitors is illegal. Healthcare increasingly relies on joint ventures, accountable care organizations, and physician networks that can deliver real benefits to patients. The DOJ and FTC evaluate these under the Rule of Reason, looking for whether the collaboration produces efficiencies that outweigh competitive harm and whether restrictions on competition are reasonably necessary to achieve them.

Financial or Clinical Integration

Joint price negotiations by a network of competing providers are permissible when the network is genuinely integrated. Financial integration typically means providers share substantial financial risk — accepting capitated payments (a fixed amount per patient regardless of services rendered) or significant payment withholds tied to cost or quality benchmarks.¹⁷ Clinical integration is the alternative path: real investment in shared infrastructure to monitor quality, coordinate treatment protocols, and control costs jointly. Regulators look for shared electronic health records, joint utilization review, and quality metrics that affect compensation, not a written policy sitting in a filing cabinet.

Exclusive Contracts

Exclusive contracts between providers and payers are also evaluated under the Rule of Reason. Legality hinges on whether the entity imposing the exclusivity has significant market power and whether the restrictions are reasonably necessary for the arrangement to function. A small physician network requiring exclusivity in a large, competitive metro area is far less concerning than a dominant hospital system doing the same thing in a rural market with no alternatives.

Antitrust Safety Zones

The DOJ and FTC have published safety zones for arrangements that pose minimal competitive risk. For hospital mergers, the agencies generally won’t challenge a deal when one hospital has averaged fewer than 100 licensed beds and an average daily census below 40 patients over the prior three years.¹⁸

For physician network joint ventures, the thresholds depend on exclusivity. An exclusive network (where participating physicians can’t join competing networks) generally falls within the safety zone if it includes 20 percent or fewer of the physicians in each relevant specialty in the geographic market. A non-exclusive network gets more room, up to 30 percent.¹⁸ Both types must involve substantial financial risk-sharing among participants. Falling outside these safety zones doesn’t mean an arrangement is illegal; it means the agencies will analyze it more carefully.

Exemptions People Rely On (and Often Misread)

Several doctrines carve out exceptions to federal antitrust liability. Organizations sometimes rely on these exemptions without actually meeting the requirements.

State Action Immunity

Under the state action doctrine, established by the Supreme Court in Parker v. Brown (1943), a state can authorize anti-competitive regulation without violating federal antitrust law. When a state delegates that authority to a private entity like a professional licensing board, two conditions must be met: the restraint must be “clearly articulated and affirmatively expressed” as state policy, and the state must actively supervise the private entity’s conduct.¹⁹

The Supreme Court tightened this standard in North Carolina State Board of Dental Examiners v. FTC (2015), holding that when a regulatory board is controlled by active market participants (which describes most medical licensing boards), active supervision by a politically accountable government official is required. A board composed of practicing dentists or physicians can’t simply regulate competitors and claim state action immunity without genuine state oversight.

The Partial Repeal of McCarran-Ferguson

For decades, the McCarran-Ferguson Act gave insurance companies a limited exemption from federal antitrust law for conduct qualifying as the “business of insurance,” provided state law regulated the activity. The Competitive Health Insurance Reform Act of 2020 partially repealed this exemption for health insurance, including dental insurance, effective January 2021.²⁰ Health insurers can still collaborate on actuarial data, historical loss data, and standard policy form development without antitrust exposure, but the broad “business of insurance” shield no longer protects them from federal competition law.

Nonprofit Status Is Not a Shield

A common misconception is that nonprofit hospitals are exempt from antitrust enforcement. They are not. The FTC and DOJ have challenged mergers involving nonprofit hospitals and investigated anti-competitive conduct by nonprofit health systems for decades. Tax-exempt status has no bearing on whether a hospital’s market behavior harms competition.

How to Report a Violation

The DOJ, FTC, and Department of Health and Human Services maintain a joint healthcare competition enforcement initiative. If you suspect anti-competitive behavior, whether price-fixing among local providers, a no-poach agreement suppressing wages, or a merger eliminating your options, you can submit a complaint through the DOJ Antitrust Division’s online healthcare competition complaint form.²¹ The information you provide is voluntary but helps the agencies identify patterns and open investigations. The form is specifically for competition concerns; billing disputes, coverage denials, and insurance rate complaints go through other channels.²²

Beyond government enforcement, the Clayton Act’s treble damages provision gives private parties a strong incentive to bring their own suits. A physician group squeezed out of a market by exclusionary contracts, or a health plan forced to pay inflated rates because of provider collusion, can sue in federal court and recover three times its actual losses.⁴

1
Antitrust Division. The Antitrust Laws
2
Office of the Law Revision Counsel. 15 USC 1 – Trusts, Etc., in Restraint of Trade Illegal
3
Office of the Law Revision Counsel. 15 USC 18 – Acquisition by One Corporation of Stock of Another
4
Legal Information Institute. Clayton Antitrust Act
5
Office of the Law Revision Counsel. 15 USC 45 – Unfair Methods of Competition Unlawful
6
Federal Trade Commission. Federal Trade Commission Act
7
Office of the Law Revision Counsel. 15 USC 13 – Discrimination in Price, Services, or Facilities
8
U.S. Department of Justice. Healthcare and Consumer Products Section
9
Federal Trade Commission. Health Care Competition
10
National Association of Attorneys General. Antitrust
11
U.S. Department of Justice. Jury Convicts Home Health Agency Executive of Fixing Wages
12
United States Department of Justice. Merger Guidelines – 4.3 Market Definition
13
Federal Trade Commission. FTC Announces 2026 Update of Jurisdictional and Fee Thresholds for Premerger Notification Filings
14
Federal Trade Commission. Premerger Notification and the Merger Review Process
15
Federal Trade Commission. Negotiating Merger Remedies
16
Federal Trade Commission. Hospitals and Clinics
17
Federal Trade Commission. Antitrust Analysis of Hospital Networks and Shared Services Arrangements
18
Federal Trade Commission. Statements of Antitrust Enforcement Policy in Health Care
19
National Association of Attorneys General. State Action Immunity Update
20
Congress.gov. Competitive Health Insurance Reform Act of 2020
21
U.S. Department of Justice. Healthcare Competition Complaint
22
United States Department of Justice. Submit a Complaint About Healthcare Competition